Canada Life’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,167
| Closed | -$222K | – | 2253 |
|
|
2023
Q2 | $222K | Buy |
2,167
+888
| +69% | +$84K | ﹤0.01% | 1818 |
|
|
2023
Q1 | $116K | Sell |
1,279
-224
| -15% | -$13.1K | ﹤0.01% | 1963 |
|
|
2022
Q4 | $57K | Hold |
1,503
| – | – | ﹤0.01% | 2062 |
|
|
2022
Q3 | $38K | Hold |
1,503
| – | – | ﹤0.01% | 2152 |
|
|
2022
Q2 | $46K | Hold |
1,503
| – | – | ﹤0.01% | 2075 |
|
|
2022
Q1 | $52K | Hold |
1,503
| – | – | ﹤0.01% | 2147 |
|
|
2021
Q4 | $40K | Hold |
1,503
| – | – | ﹤0.01% | 2236 |
|
|
2021
Q3 | $152K | Hold |
1,503
| – | – | ﹤0.01% | 1965 |
|
|
2021
Q2 | $212K | Hold |
1,503
| – | – | ﹤0.01% | 1917 |
|
|
2021
Q1 | $148K | Sell |
1,503
-78
| -5% | -$9.1K | ﹤0.01% | 2018 |
|
|
2020
Q4 | $195K | Hold |
1,581
| – | – | ﹤0.01% | 1972 |
|
|
2020
Q3 | $154K | Hold |
1,581
| – | – | ﹤0.01% | 1953 |
|
|
2020
Q2 | $244K | Buy |
1,581
+216
| +16% | +$32.8K | ﹤0.01% | 1864 |
|
|
2020
Q1 | $199K | Hold |
1,365
| – | – | ﹤0.01% | 1812 |
|
|
2019
Q4 | $277K | Buy |
+1,365
| New | +$249K | ﹤0.01% | 1854 |
|
|
2019
Q3 | – | Sell |
-2,510
| Closed | -$237K | – | 2447 |
|
|
2019
Q2 | $237K | Sell |
2,510
-442
| -15% | -$38.2K | ﹤0.01% | 1985 |
|
|
2019
Q1 | $251K | Buy |
2,952
+921
| +45% | +$76.5K | ﹤0.01% | 1820 |
|
|
2018
Q4 | $110K | Buy |
2,031
+1,131
| +126% | +$69.1K | ﹤0.01% | 2116 |
|
|
2018
Q3 | $74K | Hold |
900
| – | – | ﹤0.01% | 2294 |
|
|
2018
Q2 | $31K | Hold |
900
| – | – | ﹤0.01% | 2480 |
|
|
2018
Q1 | $18K | Hold |
900
| – | – | ﹤0.01% | 2512 |
|
|
2017
Q4 | $25K | Hold |
900
| – | – | ﹤0.01% | 2480 |
|
|
2017
Q3 | $28K | Hold |
900
| – | – | ﹤0.01% | 2452 |
|
|
2017
Q2 | $28K | Buy |
+900
| New | +$22.1K | ﹤0.01% | 2452 |
|
Other funds holding RETA
Canada Life's RETA Position: Q3 2023 in Review
Canada Life sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2,167 shares — an estimated $222K sold.
Canada Life first reported a position in RETA in Q2 2017 and held it in 24 quarters. The position peaked at $277K in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Canada Life reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Canada Life sold 2,167 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $222K.
- Canada Life first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2017 and held it in 24 quarters.
- Canada Life's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $277K in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Canada Life's 13F filing for Q3 2023, filed 14 Nov 2023.